Commerzbank Aktiengesellschaft FI Buys 464 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Commerzbank Aktiengesellschaft FI raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,463 shares of the biopharmaceutical company’s stock after buying an additional 464 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Gilead Sciences were worth $963,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bellevue Group AG raised its stake in Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after buying an additional 7,093 shares during the period. Quantinno Capital Management LP grew its position in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares during the last quarter. McAdam LLC grew its position in shares of Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC grew its position in shares of Gilead Sciences by 2.6% in the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after purchasing an additional 9,791 shares during the last quarter. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its position in shares of Gilead Sciences by 3.9% in the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company’s stock valued at $13,132,000 after purchasing an additional 5,382 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares in the company, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 293,356 shares of company stock valued at $29,166,240 over the last three months. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 1.1 %

Shares of NASDAQ:GILD opened at $114.74 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $117.39. The firm has a fifty day moving average of $98.28 and a 200 day moving average of $90.74. The firm has a market capitalization of $143.00 billion, a PE ratio of 310.11, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Royal Bank of Canada upped their target price on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Citigroup began coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target on the stock. The Goldman Sachs Group increased their price target on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Finally, Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $102.76.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.